Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.78
+2.51 (1.22%)
AAPL  273.92
+7.74 (2.91%)
AMD  209.32
+12.72 (6.47%)
BAC  49.84
-1.23 (-2.42%)
GOOG  309.71
-1.98 (-0.64%)
META  636.61
-0.64 (-0.10%)
MSFT  386.96
+2.49 (0.65%)
NVDA  191.84
+0.29 (0.15%)
ORCL  145.84
+4.53 (3.21%)
TSLA  407.25
+7.42 (1.86%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.